Abstract
Vitamin D receptor (VDR) gene FokI (rs2228570) polymorphism was postulated to influence outcome of several inflammatory diseases. The aim of this study was to evaluate the influence of rs2228570 polymorphism on lipid profile and on outcome in patients with juvenile idiopathic arthritis (JIA) treated with etanercept. A total of 153 subjects (62 JIA patients and 91 controls) were screened for the rs2228570 using the PCR-RFLP method. Lipid profile (cholesterol, triacylglycerol, HDL-C, and LDL-C) was determined using standard biochemical analysis in controls, while in JIA patients, it was determined prior to and 12 months after anti-TNF (etanercept) therapy. Clinical outcome was assessed using the JIA—American College of Rheumatology (ACR) response criteria. There were significant differences in the distribution of genotypes (p = 0.024) and alleles (p = 0.006; OR = 2.222, 95% CI 1.136–4.348) of the rs2228570 between patients and controls. Etanercept treatment significantly increased HDL-C levels (p = 0.006) in JIA patients with FF genotype in comparison to baseline values. No significant differences were seen in JIA—ACR 30/50/70 responses at month 12 between FF and Ff/ff genotype carriers. This is the first study to demonstrate the protective effect of the VDR FokI FF genotype on lipid profile in JIA patients treated with etanercept. However, this has to be confirmed in a larger cohort of patients.
Similar content being viewed by others
References
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392
Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344(12):907–916. https://doi.org/10.1056/NEJM200103223441207
Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T, QUEST-RA Group (2008) Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10(2):R30. https://doi.org/10.1186/ar2383
Shen CC, Yao TC, Yeh KW, Huang JL (2013) Association of disease activity and anti-rheumatic treatment in juvenile idiopathic arthritis with serum lipid profiles: a prospective study. Semin Arthritis Rheum 42(6):590–596. https://doi.org/10.1016/j.semarthrit.2012.10.002
Breda L, Gaspari S, Chiarelli F, Di Marzio D, Nozzi M, Mohn A et al (2013) Relationship between inflammatory markers, oxidant–antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol 102(1):63–71. https://doi.org/10.1007/s00392-012-0496-3
Yeh K, Lee CM, Chang CJ, Lin YJ, Huang JL (2014) Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-a treatment. PLoS One 9(6):e90757. https://doi.org/10.1371/journal.pone.0090757
Vojinovic J (2014) Vitamin D receptor agonists’ anti-inflammatory properties. Ann N Y Acad Sci 1317:47–56. https://doi.org/10.1111/nyas.12429
Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, Tavakkoli P, Galligan MA, Dang HTL, Haussler CA, Haussler MR (2000) The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 14(3):401–420. https://doi.org/10.1210/mend.14.3.0435
Reis JP, von Mühlen D, Miller ER 3rd, Michos ED, Appel LJ (2009) Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 124(3):e371–e379. https://doi.org/10.1542/peds.2009-0213
Kamen D, Aranow C (2008) Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol 20(5):532–537. https://doi.org/10.1097/BOR.0b013e32830a991b
Cutolo M, Otsa K, Paolino S, Yprus M, Veldi T, Seriolo B (2009) Vitamin D involvement in rheumatoid arthritis and systemic lupus erythaematosus. Ann Rheum Dis 68(3):446–447. https://doi.org/10.1136/ard.2008.093476
Mowla K, Saki MA, Jalali MT Zayeri ZD (2017) How to manage rheumatoid arthritis according to classic biomarkers and polymorphisms? Front Biol 12(3):183–191. https://doi.org/10.1007/s11515-017-1452-4
Ensembl base (2018). Transcript: VDR-201. https://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000111424;r=12:47841537-47943048;t=ENST00000229022. Accessed 14 May 2018
Karray EF, Ben Dhifallah I, Ben Abdelghani K, Ben Ghorbel I, Khanfir M, Houman H, Hamzaoui K, Zakraoui L (2012) Associations of vitamin D receptor gene polymorphisms FokI and BsmI with susceptibility to rheumatoid arthritis and Behchet’s disease in Tunisians. Joint Bone Spine 79(2):144–148. https://doi.org/10.1016/j.jbspin.2011.06.003
Goertz B, Fassbender WJ, Williams JC, Marzeion AM, Bretzel RG, Stracke H, Berliner MN (2003) Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients. Clin Exp Rheumatol 21(3):333–339
Lee YH, Bae SC, Choi SJ, Ji JD, Song GG (2011) Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 38(6):3643–3651. https://doi.org/10.1007/s11033-010-0477-4
Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP (2017) Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther 19(1):256. https://doi.org/10.1186/s13075-017-1462-2
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202–1209
Pani MA, Knapp M, Donner H, Braun J, Baur MP, Usadel KH, Badenhoop K (2000) Vitamin D receptor allele combinations influence genetic susceptibility to type 1 diabetes in Germans. Diabetes 49(3):504–507
Masi L, Cimaz R, Simonini G, Bindi G, Stagi S, Gozzini A, Malentacchi C, Brandi ML, Falcini F (2002) Association of low bone mass with vitamin D receptor gene and calcitonin receptor gene polymorphisms in juvenile idiopathic arthritis. J Rheumatol 29(10):2225–2231
De Sanctis S, Marcovecchio ML, Gaspari S, Del Torto M, Mohn A, Chiarelli F et al (2013) Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. J Rheumatol 40(6):943–948. https://doi.org/10.3899/jrheum.121281
Williams C, Hayman L, Daniels S, Robinson T, Steinberger J, Paridon S, Bazzarre T (2002) Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 106(1):143–160
van Eijk I, de Vries M, Levels J, Peters M, Huizer E, Dijkmans B et al (2009) Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 60(5):1324–1330. https://doi.org/10.1002/art.24492
Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48(4):1093–1101. https://doi.org/10.1002/art.10885
Halbig M, Horneff G (2009) Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 30(2):229–238. https://doi.org/10.1007/s00296-009-0942-3
Pelajo CF, Lopez-Benitez JM, Kent DM, Price LL, Miller LC, Dawson-Hughes B (2012) 25-hydroxyvitamin D levels and juvenile idiopathic arthritis: is there an association with disease activity? Rheumatol Int 32(12):3923–3929. https://doi.org/10.1007/s00296-011-2287-y
Stagi S, Bertini F, Cavalli L, Matucci-Cerinic M, Brandi ML, Falcini F (2014) Determinants of vitamin D levels in children, adolescents, and young adults with juvenile idiopathic arthritis. J Rheumatol 41(9):1884–1892. https://doi.org/10.3899/jrheum.131421
Vojinovic J, Cimaz R (2015) Vitamin D—update for the pediatric rheumatologists. Pediatr Rheumatol Online J 13(18):18. https://doi.org/10.1186/s12969-015-0017-9
Maruotti N, Cantatore FP (2010) Vitamin D and the immune system. J Rheumatol 37(3):491–495. https://doi.org/10.3899/jrheum.090797
Won S, Sayeed I, Peterson BL, Wali B, Kahn JS, Stein DG (2015) Vitamin D prevents hypoxia/reoxygenation induced blood-brain barrier disruption via vitamin D receptor-mediated NF-kB signaling pathways. PLoS One 10(3):e0122821. https://doi.org/10.1371/journal.pone.0122821
Xiang W, Hu ZL, He XJ, Dang XQ (2016) Intravenous transfusion of endothelial progenitor cells that overexpress vitamin D receptor inhibits atherosclerosis in apoE-deficient mice. Biomed Pharmacother 84:1233–1242. https://doi.org/10.1016/j.biopha.2016.10.042
Andrukhova O, Slavic S, Zeitz U, Riesen SC, Heppelmann MS, Ambrisko TD, Markovic M, Kuebler WM, Erben RG (2014) Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol 28(1):53–64. https://doi.org/10.1210/me.2013-1252
Chow EC, Magomedova L, Quach HP, Patel R, Durk MR, Fan J et al (2014) Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol. Gastroenterology 146(4):1048–1059. https://doi.org/10.1053/j.gastro.2013.12.027
Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K et al (1997) A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 12(6):915–992
Alexeeva EI, Namazova-Baranova LS, Bzarova TM, Valieva SI, Denisova RV, Sleptsova TV, Isaeva KB, Chomahidze AM, Taibulatov NI, Fetisova AN, Karaseva AV, Baranov AA (2017) Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr Rheumatol Online J 15(1):51. https://doi.org/10.1186/s12969-017-0178-9
Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Gulli R et al (2017) Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. Mod Rheumatol Aug 24:1–15. https://doi.org/10.1080/14397595.2017.1366006
Basic J, Pavlovic D, Jevtovic-Stoimenov T, Vojinovic J, Susic G, Stojanovic I, Kocic G, Milosevic V, Cvetkovic T, Marinkovic M, Veljkovic A (2010) Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-α-308GG genotype. J Physiol Biochem 66(2):173–180. https://doi.org/10.1007/s13105-010-0022-x
Jevtovic Stoimenov T, Despotovic M, Stojanovic S, Basic J, Pavlovic D (2017) Polymorphic variants of antioxidative defense enzymes and their gene-gene epistatic interactions in systemic lupus erythematode patients. Clin Rheumatol 36(9):2019–2026. https://doi.org/10.1007/s10067-017-3755-x
Despotovic M, Jevtovic Stoimenov T, Stankovic I, Basic J, Pavlovic D (2017) Vitamin D receptor gene polymorphisms in Serbian patients with bronchial asthma: a case-control study. J Cell Biochem 118(11):3986–3992. https://doi.org/10.1002/jcb.26054
Funding
This work was supported by the Ministry of Education, Science, and Technological Development of the Republic of Serbia (grant number III41018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All participants voluntarily agreed to participate in the research, and informed consent was signed by parents or by the patients if they were aged ≥ 12 years. The Ethical Committee of the Medical Faculty in Niš gave consent for conducting this study. All participants were treated in accordance with the Helsinki Declaration. The research was conducted in the Laboratory for Functional Genomics and Proteomics, at the Medical Faculty, University of Niš, Serbia.
Conflict of interests
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Bašić, J., Vojinović, J., Jevtović-Stoimenov, T. et al. Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis. Clin Rheumatol 38, 117–124 (2019). https://doi.org/10.1007/s10067-018-4264-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4264-2